Wall Street RegretsThe regret calculator.

What if you'd held HALO?

A $1,000 investment in Halozyme Therapeutics, Inc. (HALO) at the month-end close of 2004-03 would be worth $24,740 at the close of 2026-08 — +2374.0% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $6,844.

$1,000 since 2004$24,740Total return+2374.0%Multiple24.7×CAGR+15.4%

Your scenario

Dates resolve to the nearest month-end close.
Leave empty for "held until today".
Invested at each month-end. Starts on the buy date.

Result

Worth$24,740Gain+$23,740 (+2374.0%)Multiple24.7×CAGR+15.4%

    If you'd bought $1,000 at the start of each year

    Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.

    2004$24,7402005$48,9182006$59,1322007$13,3692008$15,1362009$19,2182010$18,3342011$13,5882012$11,3172013$16,0392014$7,1792015$11,1522016$6,2102017$10,8932018$5,3122019$7,3562020$6,0702021$2,5202022$2,6762023$1,8912024$2,9122025$2,2512026$1,599

    Every year, $1,000 from 2004

    YearValue of $1,000Year return
    2004$1,000
    2005$827-17.3%
    2006$3,659+342.3%
    2007$3,232-11.7%
    2008$2,545-21.2%
    2009$2,668+4.8%
    2010$3,600+34.9%
    2011$4,323+20.1%
    2012$3,050-29.4%
    2013$6,814+123.4%
    2014$4,386-35.6%
    2015$7,877+79.6%
    2016$4,491-43.0%
    2017$9,209+105.1%
    2018$6,650-27.8%
    2019$8,059+21.2%
    2020$19,414+140.9%
    2021$18,277-5.9%
    2022$25,864+41.5%
    2023$16,800-35.0%
    2024$21,732+29.4%
    2025$30,591+40.8%
    2026$48,918+59.9%

    Best and worst month-end to buy

    The best single month-end close to have bought HALO was 2005-03 ($1.65): $1,000 then is $65,224 today. The worst was 2026-08 ($108): $1,000 then is $1,000.

    FAQ

    What would $1,000 in HALO be worth today?

    A $1,000 investment in Halozyme Therapeutics, Inc. (HALO) at the start of 2004 would be worth about $24,740 today, a total return of +2374.0%. Dividends are reinvested in these figures.

    What were the best and worst years for HALO?

    Halozyme Therapeutics, Inc. (HALO)'s strongest calendar year since 2004 was 2006, a +342.3% return — $1,000 held through that year became about $4,423 by year-end. Its weakest year was 2016, at -43.0%.

    Does the calculator include dividends and splits?

    Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.

    How much would $100 per month in HALO have grown?

    Investing $100 at the end of every month since 2004-03 would have grown to about $362,520 on $27,000 invested.

    Did HALO beat the S&P 500?

    Over the same period, $1,000 in the S&P 500 index would be worth $6,844. HALO beat the S&P 500 by +261.5% in total return.

    Is this investment advice?

    No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.

    Methodology

    Halozyme Therapeutics, Inc. (HALO) historical total-return data from 2004-03 to 2026-08, reduced to month-end closes for the tables above.

    Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.

    Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.

    Full methodology →

    What if you'd held…

    Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.